Curr Med Chem 30(22):24762479 Trevaskis JL, Griffin PS, Wittmer C, Neuschwander-Tetri BA, Brunt EM, Dolman CS, Erickson MR, Napora J, Parkes DG, Roth JD (2012) Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice
Regular IGF-1 clears faster and requires more frequent dosing to maintain steady receptor activation, but IGF-1 LR3s extended duration simplifies protocol logistics while demanding more precise timing to avoid receptor downregulation and hypoglycemia
If you develop a side effect while taking Trulicity and want to tell the FDA about it, visit MedWatch or call 800-FDA-1088
MACE=major adverse cardiovascular event
When adjusted for sequence length, the glicentin and GRPP (which is a component of glicentin) show the greatest variability ( Supplementary Table 7 )